Home » Healthcare » Checkpoint Inhibitor Refractory Cancer Market

Checkpoint Inhibitor Refractory Cancer Drugs Market By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor, Others); By Application (Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer, Others); By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Checkpoint Inhibitor Refractory Cancer Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2026-03-03
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Checkpoint Inhibitor Refractory Cancer Market

Summary
Table Of Content
Request Free Sample

Global Checkpoint Inhibitor Refractory Cancer Drugs Market

The global checkpoint inhibitor refractory cancer drugs market size was estimated at USD 42,632.94 million in 2025 and is expected to reach USD 95,548.35 million by 2032, growing at a CAGR of 12.67% from 2025 to 2032, driven by the expanding pool of patients who do not respond to, or progress after, PD-(L)1 and CTLA-4 checkpoint inhibitor therapy, which increases demand for next-line regimens and combination strategies. Continued clinical emphasis on treatment sequencing and resistance-focused approaches supports sustained adoption across high-incidence and high-treatment-intensity tumor types.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Checkpoint Inhibitor Refractory Cancer Drugs Market Size 2025	USD 42,632.94 million
Checkpoint Inhibitor Refractory Cancer Drugs Market , CAGR	12.67%
Checkpoint Inhibitor Refractory Cancer Drugs Market Size 2032	USD 95,548.35 million

Key Market Trends & Insights

The market is projected to expand at a CAGR of 12.67% during 2025–2032, reflecting rising demand for post–checkpoint inhibitor treatment pathways.
PD-1 inhibitors accounted for the largest share of 0% in 2025, supported by broad use across multiple tumor types and a continued role as a backbone in combination regimens.
Non-small cell lung cancer accounted for the largest application share of 0% in 2025, reflecting high immunotherapy penetration and rapid treatment-line sequencing in lung oncology care.
Asia Pacific is expected to grow at 84% during 2025–2032, indicating faster expansion in refractory-line immuno-oncology demand than mature regions.
Africa is expected to grow at 14% during 2025–2032, reflecting comparatively slower expansion linked to narrower access to specialty oncology infrastructure.

$Checkpoint Inhibitor Refractory Cancer Drugs Market Size$

Segment Analysis

Checkpoint inhibitor refractory cancer drugs demand is anchored in clinical pathways where patients progress following PD-(L)1 and CTLA-4 therapy and require alternative regimens to extend survival and manage disease control. This creates sustained emphasis on combination approaches and sequencing strategies across solid tumors and select hematologic malignancies, particularly where checkpoint inhibitors are widely used in earlier lines. Treatment selection is shaped by prior exposure history, biomarker status, tolerability constraints, and the ability of health systems to support complex oncology protocols.

Market activity increasingly concentrates on optimizing post-progression options within high-volume indications, which sustains utilization across hospital-based oncology settings and specialist-led care pathways. The refractory setting also tends to intensify clinical decision-making because clinicians must balance incremental efficacy with toxicity and cost considerations, especially when combinations are used. These dynamics reinforce demand for therapies that demonstrate benefit in defined post–checkpoint inhibitor populations and can fit into standardized treatment algorithms.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

By Type Insights

PD-1 inhibitor accounted for the largest share of 43.0% in 2025. This leadership reflects its broad footprint across multiple tumor types, which enlarges the base of patients who later move into refractory settings after progression. PD-1 agents also remain central to combination strategies intended to deepen response or restore sensitivity, supporting continued use across treatment lines. Familiarity with safety profiles and established clinical experience further sustains adoption in refractory-line sequencing.

By Application Insights

Non-small cell lung cancer accounted for the largest share of 37.0% in 2025. The segment leads due to high incidence and extensive checkpoint inhibitor utilization across multiple disease stages, which expands the refractory patient pool over time. Rapid movement across therapy lines and frequent evaluation of combination regimens increase treatment intensity in this setting. These factors keep NSCLC at the center of refractory-line innovation and clinical adoption.

By Sales Channel Insights

Hospital pharmacies remain critical for checkpoint inhibitor refractory cancer drug access because many regimens require specialist oversight, protocol-driven dosing, and monitoring within oncology centers. Reimbursement processing, payer controls, and formulary governance also reinforce hospital-led distribution for complex immuno-oncology use. Retail and online channels typically play a supporting role where specialty pharmacy models are used, particularly for adjunct therapies or components integrated into broader care pathways. Channel mix continues to be shaped by site-of-care shifts and the availability of outpatient oncology delivery models.

Checkpoint Inhibitor Refractory Cancer Drugs Market Drivers

Expanding Refractory Patient Pool Following Checkpoint Inhibitor Use

Checkpoint inhibitors are used across a growing set of tumor types and treatment lines, which increases the number of patients who eventually progress or fail to respond. This enlarges the addressable population requiring refractory-line therapies and post-progression sequencing options. Clinicians increasingly require structured approaches to manage primary resistance and acquired resistance after PD-(L)1 or CTLA-4 exposure. These conditions sustain demand for therapies that can deliver benefit in previously treated, difficult-to-manage patient populations.

Intensifying Focus on Combination and Sequencing Strategies

Refractory disease management increasingly depends on combination approaches designed to overcome resistance mechanisms. Treatment regimens are selected to balance efficacy with safety, particularly in heavily pretreated patients. As sequencing pathways mature, drug utilization becomes more protocol-driven, supporting consistent demand across oncology centers. The focus on optimizing post-progression outcomes strengthens continued investment in therapies positioned for refractory settings.

For instance, Bristol Myers Squibb’s RELATIVITY-047 study (nivolumab + relatlimab vs nivolumab in advanced melanoma) reported a median progression-free survival of 10.2 months for the combination vs 4.6 months for nivolumab alone, with an objective response rate of 43.7% vs 33.7%, demonstrating measurable benefit from dual-checkpoint strategies that expand post-progression planning options.

High Treatment Intensity in Major Solid Tumors

Large-volume cancers such as non-small cell lung cancer and kidney cancer sustain high checkpoint inhibitor exposure, which feeds refractory demand over time. The clinical need remains acute because progression after immunotherapy often limits options and elevates urgency for next-line therapies. Ongoing improvements in diagnostics and treatment algorithms increase the number of eligible patients and refine treatment selection. These factors reinforce sustained market expansion in high-incidence tumor categories.

For instance, in the 5-year update of CheckMate 214 in advanced renal cell carcinoma (nivolumab + ipilimumab vs sunitinib), 48% of patients treated with nivolumab + ipilimumab were alive at 5 years (vs 37% with sunitinib), and complete response rates at long follow-up were reported as 10.7% (vs 2.6%), underscoring both high treatment intensity and the sizable population that ultimately requires later-line decisions after IO exposure.

Access Expansion Across Regions and Care Settings

Health systems continue to broaden access to immuno-oncology through improved coverage, expanding specialty oncology capacity, and wider treatment availability. As checkpoint inhibitor use becomes more normalized, refractory-line demand follows, especially in regions where earlier-line adoption is accelerating. Provider networks and oncology centers are also strengthening care pathways that can support complex therapies. This creates a broader foundation for refractory cancer drug utilization over the forecast period.

Checkpoint Inhibitor Refractory Cancer Drugs Market Challenges

Clinical heterogeneity in refractory disease creates variability in treatment response, making it difficult to standardize regimens across patient subgroups. Prior therapy exposure, biomarker status, and comorbidity burden can materially affect outcomes and tolerability, which complicates clinical decision-making. In addition, combination regimens can increase toxicity management burden, limiting use in frail or heavily pretreated populations. These constraints can slow uptake in settings where monitoring resources are limited.

For instance, the FDA label for Janssen’s TECVAYLI (teclistamab-cqyv) specifies hospitalization for 48 hours after administration of all step-up doses, and reports cytokine release syndrome (CRS) in 72% of patients at the recommended dose (Grade 1: 50%, Grade 2: 21%, Grade 3: 0.6%)—a concrete example of how advanced regimens can impose significant monitoring and toxicity-management requirements.

Market access and affordability remain significant barriers, particularly where reimbursement is restrictive or specialty oncology services are concentrated in a limited number of centers. Treatment pathways may also be influenced by formulary controls and payer-driven sequencing requirements. Regional disparities in diagnostic capacity and specialist availability can constrain eligible patient identification. These issues are most pronounced in parts of Latin America, the Middle East, and Africa, where access can be uneven across countries and care settings.

Checkpoint Inhibitor Refractory Cancer Drugs Market Trends and Opportunities

Clinical pathways are increasingly shaped by resistance-informed strategies, including biomarker-guided selection and regimen optimization after PD-(L)1 progression. This trend supports opportunities for therapies that can show benefit in well-defined refractory populations and integrate into established sequencing algorithms. Growth also benefits from ongoing expansion of immunotherapy use into earlier disease stages, which increases the downstream refractory pool over time. Treatment standardization in major oncology centers supports faster diffusion of updated protocols.

For instance, Roche-owned Foundation Medicine’s FDA-approved FoundationOne CDx is designed to profile 324 genes and report genomic signatures such as microsatellite instability (MSI) and tumor mutational burden (TMB), supporting biomarker-driven treatment selection in routine oncology workflows.

Opportunities also arise from expanding oncology capacity in fast-growing regions, particularly Asia Pacific, where infrastructure growth and broader access can accelerate uptake. As oncology service delivery models evolve, specialty pharmacy and outpatient care pathways may expand, supporting smoother distribution and patient management. Greater emphasis on coordinated care pathways can improve persistence and adherence where applicable. These shifts create room for differentiated therapies and regimen strategies that align with real-world clinical constraints.

Regional Insights

North America

North America is expected to grow at 12.06% during 2025–2032, supported by high immunotherapy penetration and established sequencing practices in specialist oncology centers. Strong clinical trial activity and structured treatment pathways reinforce adoption in refractory settings. Access is shaped by payer controls, but mature reimbursement frameworks support continued utilization in eligible patient populations.

Europe

Europe is expected to grow at 11.42% during 2025–2032, supported by guideline-based immunotherapy adoption and broad oncology infrastructure across major markets. Centralized procurement and formulary decision-making influence regimen access and sequencing in refractory care. Continued emphasis on standardized protocols supports steady demand across specialist-led oncology systems.

Asia Pacific

Asia Pacific is expected to grow at 13.84% during 2025–2032, reflecting faster expansion in oncology capacity and widening checkpoint inhibitor use across indications. Growth is reinforced by rising access to specialty cancer care and expanding treatment availability in large patient populations. As immunotherapy adoption scales, the refractory-line patient pool increases, supporting sustained demand for next-line strategies.

Latin America

Latin America is expected to grow at 9.53% during 2025–2032, with adoption influenced by expansion of private oncology networks and gradual improvements in coverage. Access remains uneven across countries, with demand concentrated in major urban centers. Treatment growth is supported as specialty infrastructure expands and immuno-oncology use becomes more integrated into care pathways.

Middle East & Africa

The Middle East is expected to grow at 8.65% during 2025–2032 and Africa at 7.14% during 2025–2032, reflecting slower overall expansion due to access concentration in higher-capability centers. Adoption is driven by specialist oncology hubs, particularly in markets with stronger reimbursement and tertiary care infrastructure. Growth remains dependent on expanding diagnostic capacity, specialist availability, and coverage for advanced oncology therapies.

Competitive Landscape

Competition in checkpoint inhibitor refractory cancer drugs is driven by positioning within post–checkpoint inhibitor sequencing, combination regimen design, and evidence generation in defined refractory populations. Companies differentiate through clinical performance in previously treated settings, tolerability of combinations, and the ability to align therapies with biomarker-driven care pathways. Market success is also influenced by payer acceptance, formulary access, and the capacity to support oncology centers with protocol integration and real-world evidence generation.

Bristol-Myers Squibb Company maintains a strong footprint in immuno-oncology through established checkpoint inhibitor portfolios and ongoing efforts to support sequencing strategies and combinations in complex oncology settings. Its competitive approach centers on reinforcing clinical relevance across multiple tumor types and supporting physician confidence through evidence development and pathway integration. Continued emphasis on refractory-relevant treatment strategies supports differentiation in patient populations where post-progression options are limited. These factors help sustain competitive positioning as refractory demand expands.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

Bristol-Myers Squibb Company
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Exelixis, Inc.
AstraZeneca plc
GSK plc
F. Hoffmann-La Roche Ltd
Eisai Co., Ltd.
Others

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Recent Developments

In June 2025, Teva Pharmaceutical Industries and Fosun Pharma announced a strategic partnership to develop TEV‑56278, described as an investigational anti‑PD1‑IL2 “ATTENUKINE” therapy intended to accelerate clinical data generation across cancers including melanoma.
In June 2025, Bristol-Myers Squibb Company and BioNTech announced a global strategic partnership to jointly develop and commercialize BioNTech’s oncology candidate BNT327, positioning it as a potential next-generation immuno-oncology backbone beyond single-mechanism checkpoint inhibitors
In March 2025, Sun Pharmaceutical Industries announced it would acquire Checkpoint Therapeutics, highlighting Checkpoint’s FDA-approved anti‑PD‑L1 therapy UNLOXCYT (cosibelimab‑ipdl) as part of the transaction.
In February 2024, Iovance Biotherapeutics received FDA accelerated approval for lifileucel (Amtagvi) for adults with unresectable or metastatic melanoma previously treated with a PD‑1–blocking antibody (and targeted therapy if BRAF V600–positive), creating a new commercial option specifically for a checkpoint-inhibitor–refractory/experienced population.

Report Scope

Report Attribute	Details
Market size value in 2025	USD 42,632.94 million
Revenue forecast in 2032	USD 95,548.35 million
Growth rate (CAGR)	12.67% (2025–2032)
Base year	2025
Forecast period	2026–2032
Quantitative units	USD million
Segments covered	By Type Outlook: CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor, Others; By Application Outlook: Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer, Others; By Sales Channel Outlook: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled	Bristol-Myers Squibb Company, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Exelixis, Inc., AstraZeneca plc, GSK plc, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Others companies
No. of Pages	322

Segmentation

BY TYPE

CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor
Others

BY APPLICATION

Hodgkin Lymphoma
Kidney Cancer
Melanoma
Non-Small Cell Lung Cancer
Others

BY SALES CHANNEL

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

BY REGION

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Table of Content
CHAPTER NO. 1 : INTRODUCTION…………………………………32
1.1. Report Description ……………………………………………………….32
Purpose of the Report……………………………………….. 32
USP & Key Offerings………………………………………….. 32
1.2. Key Benefits for Stakeholders…………………………………………33
1.3. Target Audience …………………………………………………………..33
CHAPTER NO. 2 : EXECUTIVE SUMMARY ……………………….34
CHAPTER NO. 3 : CHECKPOINT INHIBITOR REFRACTORY
CANCER MARKET FORCES & INDUSTRY
PULSE………………………………………………38
3.1. Market Overview………………………………………………………….38
3.2. Rising Global Cancer Burden and Demand for Novel
Therapies 40
3.3. Advancements in Combination Immunotherapy and Precision
Oncology 41
3.4. Biological Complexity and Heterogeneity of Resistance
Mechanisms 42
3.5. High Treatment Costs and Reimbursement Limitations………43
3.6. Expansion of Next-Generation Immunotherapies and
Personalized Treatment Approaches……………………………….44
3.7. Market Equilibrium – Porter’s Five Forces………………………..45
3.8. Ecosystem Dynamics – Value Chain Analysis……………………. 48
3.9. Macro Forces – PESTEL Breakdown ………………………………… 49
CHAPTER NO. 4 : COMPETITION ANALYSIS …………………… 52
4.1. Company Market Share Analysis……………………………………. 52
4.1.1. Global Checkpoint Inhibitor Refractory Cancer Market
Company Revenue Market Share, 2025 ………………………….. 52
4.2. Recent Key Strategic Developments Achievement……………. 54
4.3. Competitive Dashboard………………………………………………… 56
4.4. Company Assessment Metrics, 2025 ………………………………. 57
CHAPTER NO. 5 : GLOBAL MARKET ANALYSIS, INSIGHTS &
FORECAST, BY TYPE ………………………….. 58
CHAPTER NO. 6 : GLOBAL MARKET ANALYSIS, INSIGHTS &
FORECAST, BY APPLICATION………………. 62
CHAPTER NO. 7 : GLOBAL MARKET ANALYSIS, INSIGHTS &
FORECAST, BY SALES CHANNEL ………….. 66
CHAPTER NO. 8 : GLOBAL MARKET ANALYSIS, INSIGHTS &
FORECAST, BY REGION ……………………… 70
CHAPTER NO. 9 : NORTH AMERICA MARKET ANALYSIS,
INSIGHTS & FORECAST, BY COUNTRY….. 75
9.1. North America Market Analysis, Insights & Forecast, by
Type 77
9.2. North America Market Analysis, Insights & Forecast, by
Application 78
9.3. North America Market Analysis, Insights & Forecast, by Sales
Channel 79
9.4. U.S. Market Analysis, Insights & Forecast, by Type…………….80
9.5. U.S. Market Analysis, Insights & Forecast, by Application …..81
9.6. U.S. Market Analysis, Insights & Forecast, by Sales Channel .82
9.7. Canada Market Analysis, Insights & Forecast, by Type ……….83
9.8. Canada Market Analysis, Insights & Forecast, by Application84
9.9. Canada Market Analysis, Insights & Forecast, by Sales
Channel 85
9.10. Mexico Market Analysis, Insights & Forecast, by Type ……….86
9.11. Mexico Market Analysis, Insights & Forecast, by Application 87
9.12. Mexico Market Analysis, Insights & Forecast, by Sales
Channel 88
CHAPTER NO. 10 : EUROPE MARKET ANALYSIS, INSIGHTS &
FORECAST, BY COUNTRY…………………….89
10.1. Europe Market Analysis, Insights & Forecast, by Type………..92
10.2. Europe Market Analysis, Insights & Forecast, by Application 93
10.3. Europe Market Analysis, Insights & Forecast, by Sales
Channel 94
10.4. U.K. Market Analysis, Insights & Forecast, by Type ……………95
10.5. U.K. Market Analysis, Insights & Forecast, by Application…..96
10.6. U.K. Market Analysis, Insights & Forecast, by Sales Channel .97
10.7. France Market Analysis, Insights & Forecast, by Type ……….. 98
10.8. France Market Analysis, Insights & Forecast, by Application. 99
10.9. France Market Analysis, Insights & Forecast, by Sales
Channel 100
10.10. Germany Market Analysis, Insights & Forecast, by Type ….. 101
10.11. Germany Market Analysis, Insights & Forecast, by
Application 102
10.12. Germany Market Analysis, Insights & Forecast, by Sales
Channel 103
10.13. Italy Market Analysis, Insights & Forecast, by Type…………. 104
10.14. Italy Market Analysis, Insights & Forecast, by Application .. 105
10.15. Italy Market Analysis, Insights & Forecast, by Sales
Channel 106
10.16. Spain Market Analysis, Insights & Forecast, by Type……….. 107
10.17. Spain Market Analysis, Insights & Forecast, by Application 108
10.18. Spain Market Analysis, Insights & Forecast, by Sales
Channel 109
10.19. Rest of Europe Market Analysis, Insights & Forecast, by
Type 110
10.20. Rest of Europe Market Analysis, Insights & Forecast, by
Application 111
10.21. Rest of Europe Market Analysis, Insights & Forecast, by Sales
Channel 112
CHAPTER NO. 11 : ASIA PACIFIC MARKET ANALYSIS, INSIGHTS
& FORECAST, BY COUNTRY………………. 113
11.1. Asia Pacific Market Analysis, Insights & Forecast, by Type ..116
11.2. Asia Pacific Market Analysis, Insights & Forecast, by
Application 117
11.3. Asia Pacific Market Analysis, Insights & Forecast, by Sales
Channel 118
11.4. China Market Analysis, Insights & Forecast, by Type………..119
11.5. China Market Analysis, Insights & Forecast, by Application 120
11.6. China Market Analysis, Insights & Forecast, by Sales
Channel 121
11.7. Japan Market Analysis, Insights & Forecast, by Type………..122
11.8. Japan Market Analysis, Insights & Forecast, by Application 123
11.9. Japan Market Analysis, Insights & Forecast, by Sales
Channel 124
11.10. South Korea Market Analysis, Insights & Forecast, by Type 125
11.11. South Korea Market Analysis, Insights & Forecast, by
Application 126
11.12. South Korea Market Analysis, Insights & Forecast, by Sales
Channel 127
11.13. India Market Analysis, Insights & Forecast, by Type…………128
11.14. India Market Analysis, Insights & Forecast, by Application .129
11.15. India Market Analysis, Insights & Forecast, by Sales
Channel 130
11.16. Australia Market Analysis, Insights & Forecast, by Type……131
11.17. Australia Market Analysis, Insights & Forecast, by
Application 132
11.18. Australia Market Analysis, Insights & Forecast, by Sales
Channel 133
11.19. Rest of Asia Pacific Market Analysis, Insights & Forecast, by
Type 134
11.20. Rest of Asia Pacific Market Analysis, Insights & Forecast, by
Application 135
11.21. Rest of Asia Pacific Market Analysis, Insights & Forecast, by
Sales Channel 136
CHAPTER NO. 12 : LATIN AMERICA MARKET ANALYSIS,
INSIGHTS & FORECAST, BY COUNTRY… 137
12.1. Latin America Market Analysis, Insights & Forecast, by
Type 139
12.2. Latin America Market Analysis, Insights & Forecast, by
Application 140
12.3. Latin America Market Analysis, Insights & Forecast, by Sales
Channel 141
12.4. Brazil Market Analysis, Insights & Forecast, by Type……….. 142
12.5. Brazil Market Analysis, Insights & Forecast, by Application 143
12.6. Brazil Market Analysis, Insights & Forecast, by Sales
Channel 144
12.7. Argentina Market Analysis, Insights & Forecast, by Type…. 145
12.8. Argentina Market Analysis, Insights & Forecast, by
Application 146
12.9. Argentina Market Analysis, Insights & Forecast, by Sales
Channel 147
12.10. Rest of Latin America Market Analysis, Insights & Forecast, by
Type 148
12.11. Rest of Latin America Market Analysis, Insights & Forecast, by
Application 149
12.12. Rest of Latin America Market Analysis, Insights & Forecast, by
Sales Channel 150
CHAPTER NO. 13 : MIDDLE EAST MARKET ANALYSIS,
INSIGHTS & FORECAST, BY COUNTRY …151
13.1. Middle East Market Analysis, Insights & Forecast, by Type .153
13.2. Middle East Market Analysis, Insights & Forecast, by
Application 154
13.3. Middle East Market Analysis, Insights & Forecast, by Sales
Channel 155
13.4. Turkey Market Analysis, Insights & Forecast, by Type ………156
13.5. Turkey Market Analysis, Insights & Forecast, by
Application 157
13.6. Turkey Market Analysis, Insights & Forecast, by Sales
Channel 158
13.7. GCC Market Analysis, Insights & Forecast, by Type ………….159
13.8. GCC Market Analysis, Insights & Forecast, by Application…160
13.9. GCC Market Analysis, Insights & Forecast, by Sales
Channel 161
13.10. Rest of Middle East Market Analysis, Insights & Forecast, by
Type 162
13.11. Rest of Middle East Market Analysis, Insights & Forecast, by
Application 163
13.12. Rest of Middle East Market Analysis, Insights & Forecast, by
Sales Channel 164
13.13. Israel Market Analysis, Insights & Forecast, by Type……….. 165
13.14. Israel Market Analysis, Insights & Forecast, by Application 166
13.15. Israel Market Analysis, Insights & Forecast, by Sales
Channel 167
CHAPTER NO. 14 : AFRICA MARKET ANALYSIS, INSIGHTS &
FORECAST, BY COUNTRY …………………. 168
14.1. Africa Market Analysis, Insights & Forecast, by Type ………. 170
14.2. Africa Market Analysis, Insights & Forecast, by Application 171
14.3. Africa Market Analysis, Insights & Forecast, by Sales
Channel 172
14.4. Middle East Market Analysis, Insights & Forecast, by Sales
Channel 173
14.5. South Africa Market Analysis, Insights & Forecast, by Type 174
14.6. South Africa Market Analysis, Insights & Forecast, by
Application 175
14.7. South Africa Market Analysis, Insights & Forecast, by Sales
Channel 176
14.8. Egypt Market Analysis, Insights & Forecast, by Type……….. 177
14.9. Egypt Market Analysis, Insights & Forecast, by Application 178
14.10. Egypt Market Analysis, Insights & Forecast, by Sales
Channel 179
14.11. Rest of Africa Market Analysis, Insights & Forecast, by
Type 180
14.12. Rest of Africa Market Analysis, Insights & Forecast, by
Application 181
14.13. Rest of Africa Market Analysis, Insights & Forecast, by Sales
Channel 182
CHAPTER NO. 15 : COMPANY PROFILE ………………………….183
15.1. Bristol-Myers Squibb Company …………………………………….183
15.2. Merck & Co., Inc. ………………………………………………………..186
15.3. Regeneron Pharmaceuticals Inc…………………………………….189
15.4. ENB Therapeutics, Inc………………………………………………….192
15.5. Exelixis, Inc. 194
15.6. AstraZeneca 197
15.7. GSK plc 200
15.8. F. Hoffmann-La Roche Ltd…………………………………………….203
15.9. Eisai Co., Ltd 206
15.10. ImmunityBio, Inc. ……………………………………………………….209

List of Figures
FIG NO. 1. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Type, 2025 & 2032……………………………………..58
FIG NO. 2. Market Attractiveness Analysis, By Type……………………..59
FIG NO. 3. Incremental Revenue Growth Opportunity by Type, 2025 –
2032 ……………………………………………………………………..60
FIG NO. 4. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Application, 2025 & 2032…………………………….62
FIG NO. 5. Incremental Revenue Growth Opportunity by Application,
2025 – 2032…………………………………………………………….63
FIG NO. 6. Incremental Revenue Growth Opportunity by Application,
2025 – 2032…………………………………………………………….64
FIG NO. 7. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Sales Channel, 2025 & 2032 …………………………66
FIG NO. 8. Market Attractiveness Analysis, By Sales Channel………….67
FIG NO. 9. Incremental Revenue Growth Opportunity by Sales
Channel, 2025 – 2032 ……………………………………………….68
FIG NO. 10. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Region, 2025 & 2032…………………………………..70
FIG NO. 11. Market Attractiveness Analysis, By Region……………………71
FIG NO. 12. Incremental Revenue Growth Opportunity by Region, 2025
– 2032 ……………………………………………………………………72
FIG NO. 13. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Country, 2025 & 2032…………………………………75
FIG NO. 14. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Country, 2025 & 2032…………………………………89
FIG NO. 15. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Country, 2025 & 2032……………………………….113
FIG NO. 16. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Country, 2025 & 2032 ……………………………….137
FIG NO. 17. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Country, 2025 & 2032 ……………………………….151
FIG NO. 18. Checkpoint Inhibitor Refractory Cancer Market Revenue
Share, By Country, 2025 & 2032 ……………………………….168

List of Tables
TABLE NO. 1. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….61
TABLE NO. 2. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………….61
TABLE NO. 3. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………65
TABLE NO. 4. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………65
TABLE NO. 5. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…..69
TABLE NO. 6. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…..69
TABLE NO. 7. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Region, 2018 – 2024 (USD Million)…………….73
TABLE NO. 8. : Global Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Region, 2025– 2032 (USD Million) …………….74
TABLE NO. 9. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Country, 2018 – 2024 (USD Million)..76
TABLE NO. 10. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Country, 2025– 2032 (USD Million)…76
TABLE NO. 11. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2018 – 2024 (USD Million)…….77
TABLE NO. 12. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2025 – 2032 (USD Million)…….77
TABLE NO. 13. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………….78
TABLE NO. 14. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………….78
TABLE NO. 15. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2018 – 2024 (USD
Million) ………………………………………………………………….79
TABLE NO. 16. : North America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2025 – 2032 (USD
Million) ………………………………………………………………….79
TABLE NO. 17. : U.S. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….80
TABLE NO. 18. : U.S. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………….80
TABLE NO. 19. : U.S. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………81
TABLE NO. 20. : U.S. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………81
TABLE NO. 21. : U.S. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…..82
TABLE NO. 22. : U.S. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…..82
TABLE NO. 23. : Canada Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….83
TABLE NO. 24. : Canada Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………….83
TABLE NO. 25. : Canada Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………84
TABLE NO. 26. : Canada Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………84
TABLE NO. 27. : Canada Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…..85
TABLE NO. 28. : Canada Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…..85
TABLE NO. 29. : Mexico Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….86
TABLE NO. 30. : Mexico Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………….86
TABLE NO. 31. : Mexico Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………87
TABLE NO. 32. : Mexico Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………87
TABLE NO. 33. : Mexico Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…..88
TABLE NO. 34. : Mexico Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…..88
TABLE NO. 35. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2018 – 2024 (USD Million)…………..90
TABLE NO. 36. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2025– 2032 (USD Million)……………91
TABLE NO. 37. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….92
TABLE NO. 38. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)………………92
TABLE NO. 39. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………93
TABLE NO. 40. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………93
TABLE NO. 41. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…..94
TABLE NO. 42. : Europe Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…..94
TABLE NO. 43. : U.K. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….95
TABLE NO. 44. : U.K. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………….95
TABLE NO. 45. : U.K. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………96
TABLE NO. 46. : U.K. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………96
TABLE NO. 47. : U.K. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…..97
TABLE NO. 48. : U.K. Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…..97
TABLE NO. 49. : France Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………….98
TABLE NO. 50. : France Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………….98
TABLE NO. 51. : France Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)………99
TABLE NO. 52. : France Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)………99
TABLE NO. 53. : France Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…100
TABLE NO. 54. : France Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…100
TABLE NO. 55. : Germany Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..101
TABLE NO. 56. : Germany Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..101
TABLE NO. 57. : Germany Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….102
TABLE NO. 58. : Germany Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….102
TABLE NO. 59. : Germany Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…103
TABLE NO. 60. : Germany Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…103
TABLE NO. 61. : Italy Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..104
TABLE NO. 62. : Italy Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..104
TABLE NO. 63. : Italy Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….105
TABLE NO. 64. : Italy Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….105
TABLE NO. 65. : Italy Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…106
TABLE NO. 66. : Italy Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…106
TABLE NO. 67. : Spain Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..107
TABLE NO. 68. : Spain Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..107
TABLE NO. 69. : Spain Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….108
TABLE NO. 70. : Spain Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….108
TABLE NO. 71. : Spain Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…109
TABLE NO. 72. : Spain Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…109
TABLE NO. 73. : Rest of Europe Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2018 – 2024 (USD Million)…..110
TABLE NO. 74. : Rest of Europe Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2025 – 2032 (USD Million)…..110
TABLE NO. 75. : Rest of Europe Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………..111
TABLE NO. 76. : Rest of Europe Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………..111
TABLE NO. 77. : Rest of Europe Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2018 – 2024 (USD
Million) ………………………………………………………………..112
TABLE NO. 78. : Rest of Europe Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2025 – 2032 (USD
Million) ………………………………………………………………..112
TABLE NO. 79. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2018 – 2024 (USD Million)…………114
TABLE NO. 80. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2025– 2032 (USD Million)………….115
TABLE NO. 81. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..116
TABLE NO. 82. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..116
TABLE NO. 83. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….117
TABLE NO. 84. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….117
TABLE NO. 85. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…118
TABLE NO. 86. : Asia Pacific Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…118
TABLE NO. 87. : China Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..119
TABLE NO. 88. : China Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..119
TABLE NO. 89. : China Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….120
TABLE NO. 90. : China Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….120
TABLE NO. 91. : China Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…121
TABLE NO. 92. : China Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…121
TABLE NO. 93. : Japan Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..122
TABLE NO. 94. : Japan Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..122
TABLE NO. 95. : Japan Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….123
TABLE NO. 96. : Japan Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….123
TABLE NO. 97. : Japan Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…124
TABLE NO. 98. : Japan Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…124
TABLE NO. 99. : South Korea Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..125
TABLE NO. 100. : South Korea Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..125
TABLE NO. 101. : South Korea Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….126
TABLE NO. 102. : South Korea Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….126
TABLE NO. 103. : South Korea Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…127
TABLE NO. 104. : South Korea Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…127
TABLE NO. 105. : India Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..128
TABLE NO. 106. : India Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..128
TABLE NO. 107. : India Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….129
TABLE NO. 108. : India Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….129
TABLE NO. 109. : India Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…130
TABLE NO. 110. : India Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…130
TABLE NO. 111. : Australia Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..131
TABLE NO. 112. : Australia Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..131
TABLE NO. 113. : Australia Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….132
TABLE NO. 114. : Australia Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….132
TABLE NO. 115. : Australia Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…133
TABLE NO. 116. : Australia Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…133
TABLE NO. 117. : Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2018 – 2024 (USD Million)…..134
TABLE NO. 118. : Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2025 – 2032 (USD Million)…..134
TABLE NO. 119. : Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………..135
TABLE NO. 120. : Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………..135
TABLE NO. 121. : Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2018 – 2024 (USD
Million) ………………………………………………………………..136
TABLE NO. 122. : Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2025 – 2032 (USD
Million) ………………………………………………………………..136
TABLE NO. 123. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Country, 2018 – 2024 (USD Million) 138
TABLE NO. 124. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Country, 2025– 2032 (USD Million).138
TABLE NO. 125. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2018 – 2024 (USD Million)…..139
TABLE NO. 126. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2025 – 2032 (USD Million)…..139
TABLE NO. 127. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………..140
TABLE NO. 128. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………..140
TABLE NO. 129. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2018 – 2024 (USD
Million) ………………………………………………………………..141
TABLE NO. 130. : Latin America Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2025 – 2032 (USD
Million) ………………………………………………………………..141
TABLE NO. 131. : Brazil Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..142
TABLE NO. 132. : Brazil Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..142
TABLE NO. 133. : Brazil Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….143
TABLE NO. 134. : Brazil Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….143
TABLE NO. 135. : Brazil Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…144
TABLE NO. 136. : Brazil Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…144
TABLE NO. 137. : Argentina Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..145
TABLE NO. 138. : Argentina Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..145
TABLE NO. 139. : Argentina Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….146
TABLE NO. 140. : Argentina Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….146
TABLE NO. 141. : Argentina Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…147
TABLE NO. 142. : Argentina Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…147
TABLE NO. 143. : Rest of Latin America Checkpoint Inhibitor Refractory
Cancer Market Revenue, By Type, 2018 – 2024 (USD
Million)………………………………………………………………..148
TABLE NO. 144. : Rest of Latin America Checkpoint Inhibitor Refractory
Cancer Market Revenue, By Type, 2025 – 2032 (USD
Million) ………………………………………………………………..148
TABLE NO. 145. : Rest of Latin America Checkpoint Inhibitor Refractory
Cancer Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………..149
TABLE NO. 146. : Rest of Latin America Checkpoint Inhibitor Refractory
Cancer Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………..149
TABLE NO. 147. : Rest of Latin America Checkpoint Inhibitor Refractory
Cancer Market Revenue, By Sales Channel, 2018 – 2024
(USD Million)…………………………………………………………150
TABLE NO. 148. : Rest of Latin America Checkpoint Inhibitor Refractory
Cancer Market Revenue, By Sales Channel, 2025 – 2032
(USD Million)…………………………………………………………150
TABLE NO. 149. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2018 – 2024 (USD Million)…………152
TABLE NO. 150. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2025– 2032 (USD Million)………….152
TABLE NO. 151. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..153
TABLE NO. 152. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..153
TABLE NO. 153. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….154
TABLE NO. 154. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….154
TABLE NO. 155. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…155
TABLE NO. 156. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…155
TABLE NO. 157. : Turkey Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..156
TABLE NO. 158. : Turkey Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..156
TABLE NO. 159. : Turkey Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….157
TABLE NO. 160. : Turkey Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….157
TABLE NO. 161. : Turkey Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…158
TABLE NO. 162. : Turkey Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…158
TABLE NO. 163. : GCC Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..159
TABLE NO. 164. : GCC Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..159
TABLE NO. 165. : GCC Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….160
TABLE NO. 166. : GCC Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….160
TABLE NO. 167. : GCC Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…161
TABLE NO. 168. : GCC Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…161
TABLE NO. 169. : Rest of Middle East Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2018 – 2024 (USD Million)…..162
TABLE NO. 170. : Rest of Middle East Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2025 – 2032 (USD Million)…..162
TABLE NO. 171. : Rest of Middle East Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………..163
TABLE NO. 172. : Rest of Middle East Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………..163
TABLE NO. 173. : Rest of Middle East Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2018 – 2024 (USD
Million) ………………………………………………………………..164
TABLE NO. 174. : Rest of Middle East Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2025 – 2032 (USD
Million) ………………………………………………………………..164
TABLE NO. 175. : Israel Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..165
TABLE NO. 176. : Israel Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..165
TABLE NO. 177. : Israel Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….166
TABLE NO. 178. : Israel Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….166
TABLE NO. 179. : Israel Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…167
TABLE NO. 180. : Israel Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…167
TABLE NO. 181. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2018 – 2024 (USD Million)…………169
TABLE NO. 182. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Country, 2025– 2032 (USD Million)………….169
TABLE NO. 183. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..170
TABLE NO. 184. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..170
TABLE NO. 185. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….171
TABLE NO. 186. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….171
TABLE NO. 187. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…172
TABLE NO. 188. : Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…172
TABLE NO. 189. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…173
TABLE NO. 190. : Middle East Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…173
TABLE NO. 191. : South Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..174
TABLE NO. 192. : South Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..174
TABLE NO. 193. : South Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….175
TABLE NO. 194. : South Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….175
TABLE NO. 195. : South Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…176
TABLE NO. 196. : South Africa Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…176
TABLE NO. 197. : Egypt Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2018 – 2024 (USD Million)……………..177
TABLE NO. 198. : Egypt Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Type, 2025 – 2032 (USD Million)……………..177
TABLE NO. 199. : Egypt Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2018 – 2024 (USD Million)…….178
TABLE NO. 200. : Egypt Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Application, 2025 – 2032 (USD Million)…….178
TABLE NO. 201. : Egypt Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2018 – 2024 (USD Million)…179
TABLE NO. 202. : Egypt Checkpoint Inhibitor Refractory Cancer Market
Revenue, By Sales Channel, 2025 – 2032 (USD Million)…179
TABLE NO. 203. : Rest of Africa Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2018 – 2024 (USD Million)…..180
TABLE NO. 204. : Rest of Africa Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Type, 2025 – 2032 (USD Million)…..180
TABLE NO. 205. : Rest of Africa Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2018 – 2024 (USD
Million) ………………………………………………………………..181
TABLE NO. 206. : Rest of Africa Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Application, 2025 – 2032 (USD
Million) ………………………………………………………………..181
TABLE NO. 207. : Rest of Africa Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2018 – 2024 (USD
Million) ………………………………………………………………..182
TABLE NO. 208. : Rest of Africa Checkpoint Inhibitor Refractory Cancer
Market Revenue, By Sales Channel, 2025 – 2032 (USD
Million) ………………………………………………………………..182

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently asked questions

What is the market size of the global checkpoint inhibitor refractory cancer drugs market?

The market was valued at USD 42,632.94 million in 2025 and is projected to reach USD 95,548.35 million by 2032.

What is the CAGR of the global checkpoint inhibitor refractory cancer drugs market during the forecast period?

The market is expected to grow at a CAGR of 12.67% during 2025–2032.

Which segment is the largest by type in 2025?

PD-1 inhibitor is the largest type segment, accounting for 43.0% share in 2025.

What are the key factors driving growth in this market?

Growth is driven by the expanding pool of patients progressing after checkpoint inhibitor therapy, rising reliance on sequencing and combination strategies, and sustained demand in high-incidence cancers such as non-small cell lung cancer.

Who are the key players in the global checkpoint inhibitor refractory cancer drugs market?

Key players include Bristol-Myers Squibb Company, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Exelixis, Inc., AstraZeneca plc, GSK plc, F. Hoffmann-La Roche Ltd, and Eisai Co., Ltd.

Which region is expected to grow the fastest during 2025–2032?

Asia Pacific is expected to grow the fastest, with a regional CAGR of 13.84% during 2025–2032.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

AI in Clinical Trials Market

The AI in Clinical Trials Market is projected to grow from USD 2,538.43 million in 2025 to an estimated USD 12,240.4 million by 2032, registering a CAGR of 25.20% from 2025 to 2032.

Adalimumab Drugs Market

The Adalimumab Drugs Market is projected to grow from USD 14,947.5 million in 2025 to an estimated USD 21,229.73 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Acute Myeloid Leukemia Therapeutics Market

The Global Acute Myeloid Leukemia (AML) Therapeutics Market size was valued at USD 1,933.8 million in 2018 to USD 3,349.2 million in 2024 and is anticipated to reach USD 6,823.4 million by 2032, at a CAGR of 9.33% during the forecast period

Argatroban Market

The Argatroban Market is projected to grow from USD 684.95 Million in 2024 to an estimated USD 911.10 Million by 2032, with a CAGR of 4.87% from 2024 to 2032.

Breast Cancer Core Needle Biopsy Market

The global Breast Cancer Core Needle Biopsy Market size was estimated at USD 923.45 million in 2025 and is expected to reach USD 1,256.69 million by 2032, growing at a CAGR of 4.5% from 2025 to 2032.

Blood Platelets Market

The global Blood Platelets Market size was estimated at USD 6154.6 million in 2025 and is expected to reach USD 8044.68 million by 2032, growing at a CAGR of 3.9% from 2025 to 2032.

Bovine Tuberculosis Diagnosis Market

The global Bovine Tuberculosis Diagnosis Market size was estimated at USD 814.6 million in 2025 and is expected to reach USD 1086.47 million by 2032, growing at a CAGR of 4.2% from 2025 to 2032.

Bladder Cancer Therapeutics & Diagnostics Market

The global Bladder Cancer Therapeutics & Diagnostics Market size was estimated at USD 5690.23 million in 2025 and is expected to reach USD 8399.05 million by 2032, growing at a CAGR of 5.72% from 2025 to 2032.

Biotechnology Reagents Market

The global Biotechnology Reagents Market size was estimated at USD 93,978.03 million in 2025 and is expected to reach USD 184,305.19 million by 2032, growing at a CAGR of 10.1% from 2025 to 2032.

Biohazard Bags Market

The global Biohazard Bags Market size was estimated at USD 507.64 million in 2025 and is expected to reach USD 763.3 million by 2032, growing at a CAGR of 6% from 2025 to 2032.

Biguanides Market

The global Biguanides Market size was estimated at USD 18.64 million in 2025 and is expected to reach USD 23.88 million by 2032, growing at a CAGR of 3.6% from 2025 to 2032.

Biobetters Market

The global Biobetters Market size was estimated at USD 71522.2 million in 2025 and is expected to reach USD 123933.49 million by 2032, growing at a CAGR of 8.17% from 2025 to 2032.

Licence Option

Single User

$4999

Multi User

$5999

Enterprise

$7999

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample